Adam Fine is a co-founder and CEO of Windham Venture Partners. Adam is currently Director at GlySens, HelpAround, Neuspera, SubjectWell, Andros and Valera and Board Observer to Nuvaira. Chromacode, and Upward Health. Prior to Windham, Adam was VP & GM at I-many, Inc., an enterprise software company. Prior to joining I-many, Adam was a New Business Development Analyst at Cordis Corporation, a Johnson & Johnson company focused on interventional vascular devices such as stents. In that capacity, Adam worked on a range of licenses, acquisitions, divestments, as well as strategic investments with Johnson & Johnson Development Corporation (JJDC), J&J’s strategic venture arm. Prior to J&J, Adam was a research analyst at Coopers & Lybrand’s Integrated Healthcare Consulting practice.
Adam received his BA and graduated cum laude with distinction from Boston University and received his MBA from New York University.
Adam lives on the Upper West Side of Manhattan with his wife and 3 children.